JLJing Li

Jing Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects

Research Interests


Jing Li has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Guanhua Xiao

    Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Wancheng Tong

    Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Wenqi Huang

    Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Yongzhong Zhan

    Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    CircRNA_103762 promotes multidrug resistance in NSCLC by targeting DNA damage inducible transcript 3 (CHOP)

    by Guanhua Xiao, Wenqi Huang, Yongzhong Zhan, Jing Li, Wancheng Tong

    Background: CircRNAs have been found to play crucial roles in multiple tumor including non‐small cell lung cancer (NSCLC). Here, we researched the correlation between circRNA_103762 and chemotherapy resistance.Methods: RT‐PCR assay was performed to detect circRNA_103762 and DNA damage inducible transcript 3 (CHOP) expression. CCK8 assay was performed to examine cell proliferation and IC50 of different drug. Migration and invasion assay was used to detect cell migration and invasion.Results: In our study, circRNA_103762 expression was upregulated in NSCLC tissues and cell. Knockdown of circRNA_103762 can inhibited cell proliferation, migration and invasion in NSCLC. In addition, downregulation of circRNA_103762 promoted CHOP expression and inhibited multidrug resistance (MDR) in NSCLC.Conclusion: Together, we demonstrated that circRNA_103762 is upregulated in NSCLC and functions as an oncogene in NSCLC, and circRNA_103762 enhanced MDR by inhibited CHOP expression in NSCLC cells. These results will help us understand the MDR of NSCLC, providing better effective therapy strategies for patients.